Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) submitted its Monthly Return for the period ended 30 April 2026, confirming that there were no movements in either authorised or issued share capital during the month.

Authorised / Registered Capital • Total authorised capital remained at RMB 198.89 million, split between 153.28 million H-shares and 45.61 million unlisted ordinary shares, each with a par value of RMB 1.00.

Issued Shares • Issued H-shares: 153.28 million; treasury shares: zero. • Unlisted ordinary shares: 45.61 million; treasury shares: zero. • No share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled.

Public Float Leads Biolabs confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 25% for its H-share class as at 30 April 2026.

Administrative Details The return was filed on 6 May 2026 and signed by Joint Company Secretary Zuo Honggang, affirming adherence to all applicable listing rules and regulatory requirements.